v3.26.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2026
Segment Information  
Schedule of significant expense categories

The table below summarizes the significant expense categories regularly provided to the CODM for the three months ended March 31, 2026 and 2025:

Three Months Ended

March 31, 

(in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

Operating expenses:

Research and development: Firmonertinib (excluding personnel-related and other internal costs):

FURTHER

$

1,738

$

2,595

FURVENT

9,131

9,445

FAVOUR

331

2

Other Firmonertinib costs

3,883

2,262

Total Firmonertinib

15,083

14,304

Research and development: Early-stage programs

12,307

40,981

Research and development: Personnel-related and other internal costs

10,227

6,005

General and administrative: Personnel-related costs

6,183

3,331

General and administrative: Other costs

2,311

2,151

Other segment items (a)

(2,791)

(2,385)

Net loss

$

43,320

$

64,387

(a) Other segment items consists of interest and investment income.